These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

600 related items for PubMed ID: 11593415

  • 1. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.
    Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK.
    Oncogene; 2001 Sep 20; 20(42):6073-83. PubMed ID: 11593415
    [Abstract] [Full Text] [Related]

  • 2. Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.
    Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK.
    J Biol Chem; 2001 Oct 19; 276(42):38361-9. PubMed ID: 11461904
    [Abstract] [Full Text] [Related]

  • 3. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells.
    Kandasamy K, Srivastava RK.
    Cancer Res; 2002 Sep 01; 62(17):4929-37. PubMed ID: 12208743
    [Abstract] [Full Text] [Related]

  • 4. Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP.
    Rokhlin OW, Guseva NV, Tagiyev AF, Glover RA, Cohen MB.
    Prostate; 2002 Jun 01; 52(1):1-11. PubMed ID: 11992615
    [Abstract] [Full Text] [Related]

  • 5. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
    Tong X, Li H.
    Cancer Lett; 2004 Jul 08; 210(1):63-71. PubMed ID: 15172122
    [Abstract] [Full Text] [Related]

  • 6. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation.
    Bortul R, Tazzari PL, Cappellini A, Tabellini G, Billi AM, Bareggi R, Manzoli L, Cocco L, Martelli AM.
    Leukemia; 2003 Feb 08; 17(2):379-89. PubMed ID: 12592338
    [Abstract] [Full Text] [Related]

  • 7. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R, Bedi A.
    Cancer Res; 2002 Aug 01; 62(15):4180-5. PubMed ID: 12154014
    [Abstract] [Full Text] [Related]

  • 8. Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.
    Whang YE, Yuan XJ, Liu Y, Majumder S, Lewis TD.
    Vitam Horm; 2004 Aug 01; 67():409-26. PubMed ID: 15110188
    [Abstract] [Full Text] [Related]

  • 9. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2.
    Alladina SJ, Song JH, Davidge ST, Hao C, Easton AS.
    J Vasc Res; 2005 Aug 01; 42(4):337-47. PubMed ID: 15985761
    [Abstract] [Full Text] [Related]

  • 10. Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells.
    Beresford SA, Davies MA, Gallick GE, Donato NJ.
    J Interferon Cytokine Res; 2001 May 01; 21(5):313-22. PubMed ID: 11429162
    [Abstract] [Full Text] [Related]

  • 11. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.
    Munshi A, Pappas G, Honda T, McDonnell TJ, Younes A, Li Y, Meyn RE.
    Oncogene; 2001 Jun 28; 20(29):3757-65. PubMed ID: 11439339
    [Abstract] [Full Text] [Related]

  • 12. Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL).
    Eid MA, Lewis RW, Kumar MV.
    Mol Cancer Ther; 2002 Aug 28; 1(10):831-40. PubMed ID: 12492116
    [Abstract] [Full Text] [Related]

  • 13. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis.
    Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS.
    J Biol Chem; 2001 Apr 06; 276(14):10767-74. PubMed ID: 11278284
    [Abstract] [Full Text] [Related]

  • 14. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H.
    Prostate; 2004 Feb 15; 58(3):259-68. PubMed ID: 14743465
    [Abstract] [Full Text] [Related]

  • 15. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells.
    Oka N, Nakahara S, Takenaka Y, Fukumori T, Hogan V, Kanayama HO, Yanagawa T, Raz A.
    Cancer Res; 2005 Sep 01; 65(17):7546-53. PubMed ID: 16140916
    [Abstract] [Full Text] [Related]

  • 16. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
    Martelli AM, Tazzari PL, Tabellini G, Bortul R, Billi AM, Manzoli L, Ruggeri A, Conte R, Cocco L.
    Leukemia; 2003 Sep 01; 17(9):1794-805. PubMed ID: 12970779
    [Abstract] [Full Text] [Related]

  • 17. TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP.
    Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Syrbu SI, Cohen MB.
    Cancer Biol Ther; 2002 Sep 01; 1(6):631-7. PubMed ID: 12642685
    [Abstract] [Full Text] [Related]

  • 18. Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, 7, and 3 and BID cleavage in human acute myelogenous leukemia cell line HL-60.
    Lamothe B, Aggarwal BB.
    J Interferon Cytokine Res; 2002 Feb 01; 22(2):269-79. PubMed ID: 11911810
    [Abstract] [Full Text] [Related]

  • 19. Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis.
    Kim JY, Kim YH, Chang I, Kim S, Pak YK, Oh BH, Yagita H, Jung YK, Oh YJ, Lee MS.
    Oncogene; 2002 May 09; 21(20):3139-48. PubMed ID: 12082629
    [Abstract] [Full Text] [Related]

  • 20. Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase.
    Cenni V, Maraldi NM, Ruggeri A, Secchiero P, Del Coco R, De Pol A, Cocco L, Marmiroli S.
    Int J Oncol; 2004 Dec 09; 25(6):1599-608. PubMed ID: 15547696
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.